Ximelagatran and Its Risk Management Plan in United States

Abstract

Abstract: The risk management for pharmaceutical products applies toa life cycle ofa new drug development from Investigational New Drug (IND) , New Drug Application (NDA) to post -marketing. It plays a critical role in its withdrawal from the market. In this article we reviewed the risk management events of Ximelagatran(Exanta R) which is a new generation of anti-clotting drug manufactured by AstraZeneca, from its new drug approval to its withdrawal. The experience of Ximelagatran risk management in USA might provide a clue for the future risk manage ment of drug safety in China.

Key words: ximelagatran, drug risk management, risk management plan, FDA

CLC Number:

R954

GUO Jing ,GUO Jian-fei. Ximelagatran and Its Risk Management Plan in United States [J]. Chinese Journal of Pharmacovigilance, 2013, 10(2): 84-87.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/

https://zgywjj.magtechjournal.com/EN/Y2013/V10/I2/84

References

[1] FDA. NDA21-686 Ximelagatran (H376/95) Indication: Prevention of stroke and thromboembolic complications associated with atrial fibrillation[EB/OL]. FDA Regulatory Information. 2004.Available at: http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4069B1_06_FDA-Backgrounder-C-R-MOR.pdf. Accessedon August 24, 2012.
[2] HIV/AIDS News& Information. May 2010. Ximelagatran(Exanta)[EB/OL].Available at: http://www.hiv-infected.com/2010/05/ximelagatran-exanta.html. Accessed on August 24, 2012.
[3] Ho S J, BrightonTA(2006). "Ximelagatran: direct thrombin inhibitor"[J/OL]. Vasc Health Risk Manag 2(1): 49-58. Available at : http: //www.pubmedcentral.nih.gov/articlerender.fcgi tool=pmcentrez&artid=1993972. Accessed on August 24, 2012.
[4] "First launch for AstraZeneca's Exanta(ximelagatran): the first oral anticoagulant in new class of direct thrombin inhibitors (DTIs)"(Press release) [EB/OL]. AstraZeneca. June 21, 2004. Available at:
http://www.astrazeneca.com/Media/Press-releases/Article/20040621-FIRST-LAUNCH-FOR-ASTRAZENECAS-EXANTA-XIMELAGATRAN.Accessed on August 24, 2012.
[5] Schulman S,Whlander K, Lundstr. m T, et al. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran[J].The New England journal of medicine,2003,349:1713-1721.
[6] Wadman M. New tools for drug screening[J]. Nature Reports Stem Cells,2007,EISSN: 1754-8705.
[7] Marshall E."AstraZeneca's Exanta Will Surpass $2.4 Billion in Sales in 2012"[EB/OL]. Decision Resources, Inc. Available at:http://www.prnewswire.com/news-releases/astrazenecasexanta-
will-surpass-24-billion-in-sales-in-2012-accordingto-a-new-study-from-decision-resources-70838492.html.Accessed on August 24, 2012.
[8] Eriksson H, W hlander K, Gustafsson D, et al. A randomized, controlled,dose guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I [J]. Journal of Thrombosis and Haemostasis,2003,1:41-47.
[9] Vaughan C. Ximelagatran(Exanta): alternative to warfarin[J]. Proceedings(Baylor University. Medical Center). United States: Baylor Health Care System,2005,18:76-80.
[10] Summary of Product Characteristics: Exanta 24mg tablets [EB/OL].Availableat:http://www.vidyya.com/7pdfs/Exanta_PresInf_tablets.pdf. Accessed on August 24, 2012.
[11] "AstraZeneca Decides toWithdrawExanta" (Press release) [EB/OL].AstraZeneca. February 14, 2006. Available at: http://www.astrazeneca.com/Media/Press-releases/Article/20060214-AstraZeneca-Decidesto-Withdraw-Exanta. Accessed on August 24, 2012.
[12] EXANTA(ximelagatran) Tablets NDA 21-686 FDA Advisory Committee Briefing Document[EB]. September 10, 2004. AstraZeneca.1800 Concord Pike Wilmington, DE 19850.
[13] Guidance for Industry: Drug-Induced Liver Injury[EB]. July 2009. Center for Drug Evaluation and Research Food and Drug Administration. 10903 New Hampshire Ave., Bldg. 51, rm. 2201 Silver Spring, MD 20993-0002.
[14] Duffy P A, Bonner F. Stem Cells for Safer Medicines(SC4SM): A public-private consortium to enhance medicines safety assessment [J].Toxicology,2010,278:370-370.

[1]	CAO Kai, QIAN Peipei, GAO Xin, YANG Futian, ZHAO Liang, XU Bingxin, ZHANG Xianjun. Mining of Risk Signals Adverse Events Related to Drug-Induced Salivary Gland Calculus Based on FAERS Database [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 799-804.
[2]	CHEN Lingbin, HUANG Zhixiong, ZHENG Cailin, WU Jinneng, CHEN Zhou. Adverse Event Signals for Osimertinib-Induced Muscle Toxicity Based on FAERS Database [J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 447-451.
[3]	ZHAO Peipei, WEN Baoshu. Regulation of cellular and gene therapies at home and abroad [J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1019-1024.
[4]	LU De, XU Wenyan, LIU Jinxin, PEI Yusheng. Discussion and analysis of bacterial endotoxin problems in FDA warning letters [J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 857-862.
[5]	ZHONG Hong, CHEN Hong, ZHANG Xuanyi, DENG Huiyuan, LUO Xianglin, WAN Jie, KONG Wenqiang. Detection and analysis of signals of adverse events induced by deferasirox based on FAERS [J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 931-935.
[6]	YOU Xiaoyan, ZHENG Yingying, WANG Xianying. Data-mining and analysis of adverse events signals for infliximab based on FAERS database [J]. Chinese Journal of Pharmacovigilance, 2024, 21(3): 335-340.
[7]	WU Tingxi, ZHAO Zhigang, SHI Yanfeng, ZHANG Yang, ZHANG Yinan, ZHU Bin. Risk assessment of colchicine-associated neurological adverse events based on FAERS database [J]. Chinese Journal of Pharmacovigilance, 2024, 21(3): 341-345.
[8]	YE Pei, ZHANG Hewei, LYU Qiang, YE Xiaofei, XU Jinfang, GUO Xiaojing. Safety of sugammadex for reversal of neuromuscular block based on FAERS database [J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 321-325.
[9]	HAO Xiaohui, ZHANG Ping, WU Lulu, WANG Lihua. Mining and analysis of ixazomib citrate capsules safety signals based on FAERS database [J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1427-1431.
[10]	REN Yuqin, LI Xin, YU Min, SU Yuwen. Safety evaluation and comparative analysis of rituximab and adalimumab based on openFDA [J]. Chinese Journal of Pharmacovigilance, 2022, 19(7): 752-756.
[11]	ZHANG Chi. Data mining of adverse drug events of alirocumab from openFDA [J]. Chinese Journal of Pharmacovigilance, 2022, 19(6): 684-691.
[12]	CUI Xiangli, ZHANG Zhiqi, SUN Liying, GUO Mingxing, ZENG Zhigui, XU Wanyi. Leflunomide-induced hepatotoxicity: data analysis based on the FDA adverse event reporting system [J]. Chinese Journal of Pharmacovigilance, 2022, 19(4): 426-431.
[13]	ZHAO Xiaohong, GUO Mingxing, WANG Xiaojian, LIN Jianrui, CUI Xiangli. Risk signal mining related to lenvatinib based on the US FDA adverse event reporting system [J]. Chinese Journal of Pharmacovigilance, 2022, 19(11): 1233-1237.
[14]	SHA Mingquan, LI Nannan, XIA Wenjing, WEI Qun, WEN Baoshu. Research and reflection on regulatory science developments of U.S. FDA [J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1055-1059.
[15]	LING Tao, XU Ruijuan, GE Weihong. Comparison Analysis of Adverse Drug Reactions of Rivaroxaban and Apixaban Based on OpenFDA [J]. Chinese Journal of Pharmacovigilance, 2021, 18(8): 780-783.